F11 and chronic kidney disease: Future research should focus on increasing the sample sizes,randomized comparisons of DOACs to VKA, and specific studies evaluating DOACsagainst emerging anticoagulants, including FDA-approved FXI inhibitors, in CKD stage G5patients [71, 72].